Paranoid personality disorder
GPTKB entity
Statements (49)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:disease
|
| gptkbp:associated_with |
gptkb:depression
anxiety disorders |
| gptkbp:cognitive_distortion |
personalization
overgeneralization catastrophizing |
| gptkbp:community_health |
schizophrenia
bipolar disorder substance use disorders |
| gptkbp:cultural_practices |
perception varies across cultures
|
| gptkbp:diagnosis |
gptkb:ICD-10
gptkb:DSM-5 psychological evaluation clinical interview |
| gptkbp:future_prospects |
chronic condition
variable prognosis potential for improvement with treatment |
| gptkbp:historical_interpretation |
often misdiagnosed
misunderstood in early psychiatry |
| https://www.w3.org/2000/01/rdf-schema#label |
Paranoid personality disorder
|
| gptkbp:issues |
it is a rare condition
it is the same as paranoia |
| gptkbp:notable_case |
gptkb:Henry_Nixon
gptkb:John_Nash gptkb:Howard_Hughes gptkb:Joseph_Stalin gptkb:Marilyn_Monroe |
| gptkbp:premiered_on |
early adulthood
|
| gptkbp:prevalence |
0.5% to 2.5% of the population
|
| gptkbp:research_focus |
genetic predisposition
environmental triggers neurobiological factors |
| gptkbp:risk_factor |
social isolation
childhood trauma family history of mental illness |
| gptkbp:symptoms |
chronic distrust
interpretation of benign remarks as threatening pervasive jealousy suspicion of others |
| gptkbp:treatment |
gptkb:pharmaceuticals
gptkb:psychotherapy stigma lack of insight patient resistance enhance coping strategies improve social functioning reduce paranoia |
| gptkbp:bfsParent |
gptkb:Paranoia
|
| gptkbp:bfsLayer |
4
|